Online inquiry

IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6660MR)

This product GTTS-WQ6660MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC16 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6660MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9633MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ454MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ4064MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ1917MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ13949MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ1781MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ3424MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ10785MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW